Latest news with #SudarshanJain
Time of India
3 days ago
- Health
- Time of India
Pharma body opposes entry curbs on medical representatives, seeks rethink
New Delhi: The Indian Pharmaceutical Alliance (IPA), IPA, a lobby group which represents large domestic pharmaceutical companies, has raised concerns over the government's recent mandate that restricts the entry of medical representatives (MRs) into hospitals run by the Central government. The IPA has argued against the new order saying it disrupts the essential interface between pharma companies and healthcare providers and has far-reaching implications for public health, innovation, healthcare delivery , and patient care. It has urged the health ministry to have a balanced, structured, and transparent engagement model, allocating days and time for interaction. In a representation to the health ministry and department of pharmaceutical (DoP), IPA has said the diktat will impact of growth of pharmaceutical sector and result in job losses of medical representatives. "The pharmaceutical sector is knowledge driven with significant rapid advancements. Industry interactions with doctors are fundamental for knowledge development and facilitating better patient care. MRs play pivotal role for knowledge dissemination. Live Events "Guidelines have been laid between medical practitioner and industry interactions in Uniform Code of Marketing Practices and these interactions can be structured in hospital settings by allocating days and time for interactions," said Sudarshan Jain, secretary general, IPA. As ET reported last week, the Directorate General of Health Services (DGHS) has instructed all central government hospitals not to permit medical representatives in the hospital premises. Raising concerns, the IPA said that their engagement with doctors ensures timely dissemination of product-related information, covering latest advancements and access of medicines to patients. It also helps during Introduction of new therapies like complex generics and novel biologics. They also play a pivotal role in sharing clinical trial data and global research developments, supporting evidence-based practice. Economic Times WhatsApp channel )
India Gazette
13-05-2025
- Business
- India Gazette
Generics medicine industry unlikely to be impacted by Trump order: Indian Pharmaceutical Alliance
New Delhi [India], May 13 (ANI): India's generics medicine industry is unlikely to be impacted by President Donald Trump's move to slash drug prices in the US drastically, said Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA). On Monday, President Trump signed an Executive Order, which he termed as one of the 'most consequential Executive Orders' in the country's history. The order directed pharmaceutical companies to lower the prices of their medicines to align with what other countries pay for such prescription medicines. Trump gave pharmaceutical companies a 30-day deadline to cut costs or face action. 'The generics industry is unlikely to be impacted, as it operates on razor-thin margins. In the US, the generics industry represents 90 per cent of prescription volumes while accounting for only 13 per cent of the market value,' Sudarshan Jain said. The generics industry plays a pivotal role in ensuring medicines remain affordable and accessible. 'Further details on implementation mechanisms will bring more clarity,' Jain added in his brief statement on Tuesday. The Executive Order issued by the US Government seeks to balance innovation, access and overall healthcare costs. 'Research and development in life sciences demands long-term commitment, substantial investment, and carries high risk. The Order emphasises that the cost of the innovation should be shared equitably among all stakeholders,' Jain said, arguing that the innovator companies are expected to be affected with a 30-day window to align their US prices with Most-Favoured-Nation (MFN) pricing. Trump has been claiming that for many years, US consumers were paying much higher prices for medicines that are drastically lower in other countries. The US President claimed that sometimes the medicines purchased by US consumers are five to ten times more expensive than the same drug, manufactured in the exact same laboratory or plant, and by the same company. 'Prescription Drug and Pharmaceutical prices will be REDUCED, almost immediately, by 30 per cent to 80 per cent. They will rise throughout the World in order to equalize and, for the first time in many years, bring FAIRNESS TO AMERICA! I will be instituting a MOST FAVORED NATION'S POLICY whereby the United States will pay the same price as the Nation that pays the lowest price anywhere in the World. Our Country will finally be treated fairly, and our citizens Healthcare Costs will be reduced by numbers never even thought of before. Additionally, on top of everything else, the United States will save TRILLIONS OF DOLLARS,' Trump wrote on X, hours before signing the executive order. President Trump has been focusing particularly on reducing Americans' cost of living ever since he stepped into the White House for the second time. (ANI)
Economic Times
13-05-2025
- Business
- Economic Times
Trump order unlikely to impact domestic generic industry working on razor-thin profits
The domestic generic drugmakers are unlikely to be impacted by the US announcement of a 30-day deadline for companies to lower the cost of prescription medicines, industry experts say. The executive order inked by US President Donald Trump, which entails the US health department to broker new prices for prescription drugs, is, however, likely to have an adverse impact on the innovator drug firms. ADVERTISEMENT "The generics industry is unlikely to be impacted, as it operates on razor-thin margins. In the US, the generics industry represents 90 per cent of prescription volumes while accounting for only 13 per cent of the market value," IPA Secretary General Sudarshan Jain said in a statement. The generics industry plays a pivotal role in ensuring medicines remain affordable and accessible, and further details on implementation mechanisms will bring more clarity, he added. Jain noted that the order emphasises that the cost of the innovation should be shared equitably among all stakeholders. "Innovator companies are expected to be affected, with a 30-day window to align their US prices with Most-Favoured-Nation (MFN) pricing," he added. He further stated that the executive order seeks to balance innovation, access and overall healthcare costs. Research and development in life sciences demands long-term commitment, substantial investment, and carries high risk. ADVERTISEMENT The IPA is a network of 23 leading Indian drugmakers, most of whom are major exporters to the US. India is the largest supplier of generic medicines with a 20 per cent share in the global supply by manufacturing 60,000 different generic brands across 60 therapeutic categories. ADVERTISEMENT Indian products are shipped to over 200 countries around the globe, with Japan, Australia, West Europe and the US as the main destinations. India has the highest number of United States Food and Drug Administration (USFDA) compliant Pharma plants outside of USA. ADVERTISEMENT As per the fiscal year 2022 report on State of Pharmaceutical Quality published by USFDA, India boasts of more than 600 USFDA registered manufacturing sites, constituting nearly 12.5 per cent of all registered manufacturing sites operating outside the US. Economic think tank GTRI has noted that the order to cut prescription drug prices by 30-80 per cent could lead to a global price adjustment with pharma firms pushing lower-cost countries like India to raise prices. India's pharmaceutical laws fully comply with the WTO's (World Trade Organisation) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS). ADVERTISEMENT However, India has long resisted pressure to adopt TRIPS-plus provisions, additional patent protections often pushed by developed countries through FTAs. These include data exclusivity, automatic patent term extensions, patent linkage, broader patentability criteria, and evergreening practices. India does not allow data exclusivity. Instead, it permits regulatory bodies to rely on existing clinical trial data to approve generic medicines, ensuring faster and cheaper access. Saurabh Agarwal, Tax Partner, EY, said that while the move promises major savings for American consumers, it could face industry pushback and cause price increases in lower-cost countries as manufacturers seek to recover losses and R&D costs from these countries.
Time of India
13-05-2025
- Business
- Time of India
Trump order unlikely to impact domestic generic industry working on razor-thin profits
The US order to lower prescription drug prices is unlikely to impact Indian generic drugmakers, as they already operate on low margins, experts say. The move mainly affects innovator pharma companies required to align prices with global benchmarks. Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads The domestic generic drugmakers are unlikely to be impacted by the US announcement of a 30-day deadline for companies to lower the cost of prescription medicines, industry experts say. The executive order inked by US President Donald Trump , which entails the US health department to broker new prices for prescription drugs, is, however, likely to have an adverse impact on the innovator drug firms."The generics industry is unlikely to be impacted, as it operates on razor-thin margins. In the US, the generics industry represents 90 per cent of prescription volumes while accounting for only 13 per cent of the market value," IPA Secretary General Sudarshan Jain said in a generics industry plays a pivotal role in ensuring medicines remain affordable and accessible, and further details on implementation mechanisms will bring more clarity, he added. Jain noted that the order emphasises that the cost of the innovation should be shared equitably among all stakeholders."Innovator companies are expected to be affected, with a 30-day window to align their US prices with Most-Favoured-Nation (MFN) pricing," he further stated that the executive order seeks to balance innovation, access and overall healthcare and development in life sciences demands long-term commitment, substantial investment, and carries high IPA is a network of 23 leading Indian drugmakers, most of whom are major exporters to the is the largest supplier of generic medicines with a 20 per cent share in the global supply by manufacturing 60,000 different generic brands across 60 therapeutic products are shipped to over 200 countries around the globe, with Japan, Australia, West Europe and the US as the main has the highest number of United States Food and Drug Administration (USFDA) compliant Pharma plants outside of per the fiscal year 2022 report on State of Pharmaceutical Quality published by USFDA, India boasts of more than 600 USFDA registered manufacturing sites, constituting nearly 12.5 per cent of all registered manufacturing sites operating outside the think tank GTRI has noted that the order to cut prescription drug prices by 30-80 per cent could lead to a global price adjustment with pharma firms pushing lower-cost countries like India to raise prices. India's pharmaceutical laws fully comply with the WTO's (World Trade Organisation) Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS).However, India has long resisted pressure to adopt TRIPS-plus provisions, additional patent protections often pushed by developed countries through include data exclusivity, automatic patent term extensions, patent linkage, broader patentability criteria, and evergreening practices. India does not allow data exclusivity. Instead, it permits regulatory bodies to rely on existing clinical trial data to approve generic medicines, ensuring faster and cheaper Agarwal, Tax Partner, EY, said that while the move promises major savings for American consumers, it could face industry pushback and cause price increases in lower-cost countries as manufacturers seek to recover losses and R&D costs from these countries.
